Nature's Innovation, Inc. – Trademark Portfolio
Entity Type: 03
Nature's Innovation, Inc. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 20 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 17 trademarks are registered. Notable registered marks include GARLICA, BENZARID, COBRAZOL, NATURASIL, and ARACHNARID. The owner is based in Buford, GA.
5317 Palmero Court
Buford, GA 30518
Showing of trademarks Trademarks
Trademark Classifications
Nature's Innovation, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Nature's Innovation, Inc. have?
Nature's Innovation, Inc. has 25 U.S. trademarks filed with the USPTO. Of these, 17 registered, 5 abandoned, 3 cancelled.
What trademark classes does Nature's Innovation, Inc. file in?
Nature's Innovation, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Nature's Innovation, Inc.'s most well-known trademarks?
Nature's Innovation, Inc.'s registered trademark portfolio includes well-known marks such as GARLICA, BENZARID, COBRAZOL, NATURASIL, and ARACHNARID. These are among 17 currently registered trademarks in the portfolio.
What is Nature's Innovation, Inc.'s trademark registration success rate?
Nature's Innovation, Inc. has a 68% trademark registration rate, with 17 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.